FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer

FDA Approval Summary: Abemaciclib With Endocrine Therapy for High-Risk Early Breast Cancer

PURPOSE: The US Food and Drug Administration approved abemaciclib in combination with endocrine therapy (ET) for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer (EBC) at high risk of recurr...

Full description

Bibliographic Details
Main Authors: Amiri-Kordestani, L. (Author), Beaver, J.A (Author), Bloomquist, E. (Author), Ghosh, S. (Author), Kalavar, S. (Author), Mixter, B.D (Author), Mulkey, F. (Author), Osgood, C. (Author), Pazdur, R. (Author), Philip, R. (Author), Pierce, W.F (Author), Rizvi, F. (Author), Roy, A. (Author), Royce, M. (Author), Tang, S. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
abemaciclib
adult
Adult
aminopyridine derivative
Aminopyridines
antineoplastic agent
Antineoplastic Combined Chemotherapy Protocols
benzimidazole derivative
Benzimidazoles
Breast Neoplasms
breast tumor
clinical trial
disease free survival
Disease-Free Survival
epidermal growth factor receptor 2
female
Female
human
Humans
Ki 67 antigen
Ki-67 Antigen
metabolism
multicenter study
Receptor, ErbB-2
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items